To see all protocols that comply with the WHO Essential Medicine List 

Protocols and documents

If you have a protocol or document that you would like developed on eviQ, please submit your request by completing the Submit a protocol or document form. You are required to be logged into the site to complete the form.
 

A drug must be PBS listed and/or TGA registered for a particular indication in order for it to be included on the eviQ website for that indication.
 

A sufficient level of evidence to support the use of the protocol or document based on the indications and patient population, must be provided with the submission.

You will receive an initial response to your submission from the eviQ team within 7 working days.

Submissions are reviewed periodically by the relevant reference committee to decide whether the protocol or document should proceed to development.
 

The eviQ Data Governance Framework provides an overview of the process for a protocol after it has been submitted for inclusion on eviQ.

Submitted protocols that are currently being developed for inclusion on eviQ are listed on the Protocols under development page. Please check this page prior to completing the submission form.

Protocols considered and rejected for development by the reference committee can be found on the Protocols not endorsed page including the reason for rejection. Please check this page prior to completing the submission form.

A protocol or document on eviQ may have one of four statuses:

ENDORSED, UNDER REVIEW, SUPERSEDED or DISCONTINUED. 
 

A protocol or document's status is displayed in the top grey status bar:

 

For protocols or documents that are under review, discontinued or superseded, this is also included in at the end of the title in capital letters. 

Discontinued-title.jpg

  • A protocol is superseded when other treatment options are considered superior based on new evidence.
  • Superseded protocols may be clinically appropriate for some patients when considering individual circumstances.
  • Before a protocol is superseded, consensus to ‘supersede’ must be reached by the relevant eviQ reference committee.
  • Superseded protocol content remains available in its entirety on the eviQ website. 'SUPERSEDED’ is added to the protocol title and status, and the reason for superseding displayed at the top of the page.
  • As a superseded protocol may be clinically appropriate for use in some patients, it is reviewed and updated regularly by eviQ.

  • A protocol is discontinued when it is not appropriate for clinical use as it is excessively toxic or less effective compared to other treatment options, or is no longer in clinical use.
  • A discontinued protocol is one that should no longer be used to treat patients.
  • Before a protocol is discontinued, consensus to ‘discontinue’ must be reached by the relevant eviQ reference committee.
  • Discontinued protocol content is removed from the eviQ website. It is replaced with a simplified treatment schedule, related references and protocol history. ‘DISCONTINUED’ is added to the protocol title and status, and the reason for discontinuing displayed at the top of the page. 
  • As a discontinued protocol is considered not clinically appropriate, it is not reviewed or updated by eviQ.

Protocol or document version number increases when a notable change to a section is carried out. All changes are noted in the History section found by clicking on the Calendar icon  at the top right of each protocol page.

All eviQ treatment protocols are periodically reviewed every one, two or five years to ensure content is based on the latest rigorous evidence. Protocols are stratified into three groups according the following criteria:

Group 1: Annual review

Protocols to undergo a thorough review at 12 months

Protocols for which there are newer drugs with less experience of toxicity effects.

Group 2:  Two yearly review

Protocols to undergo review at 2 years from approval date, unless information becomes available that indicates a review is required before this time

Protocols for which there have been significant changes or updates in the literature and/or in clinical practice i.e. for protocols with:

  • new evidence
  • expansion of patient population through changes to the PBS/TGA
  • safety alerts.

Group 3: Five yearly review

Protocols to undergo review at 5 years, unless information becomes available that indicates a review is required before this time

Protocols for which there have been no changes or updates in the literature or in clinical practice i.e. for protocols:

  • that have been prescribed for many years where a dose change is unlikely
  • where the evidence is supported by systematic reviews
  • without safety alerts.

Please note that the following information can be found in each protocol by clicking on the information icon located next to the calculated protocol cost:

  • The cost displayed on the protocol is intended as rudimentary guide only for the Australian context.
  • The cost includes antineoplastic drugs only (not antiemetics, other supportive medications or consumables), unless otherwise indicated.
  • Drug unit costs are taken directly from the Pharmaceutical Benefits Scheme (PBS) website (www.pbs.gov.au), MIMS Online and other sources. These costs are reviewed and updated on eviQ at 6 monthly intervals.
  • Where there are differing unit costs based on vial sizes and tablet strengths, the mean unit cost is used. The cost of oral continuous therapy is based on 28 day month.
  • The protocol cost is derived from drug dose calculations based upon a default body surface area (BSA) of 1.8 m2; weight of 75 kg; and creatinine clearance of 75 mL/min.
  • One off loading doses are not included in protocol cost calculations.
  • The cost displayed is the actual drug cost and does not necessarily reflect the cost incurred by the patient as many antineoplastic drugs are reimbursed on the PBS.

On each protocol, click the patient icon  in the top bar to open  to the associated patient sheet. You can also access the patient information sheets by clicking on the patient and carers menu.

eviQ recommends that you use the Harvard AGPS referencing style to reference the eviQ website or specific eviQ content.

To cite the eviQ website as a whole:

Author (the person or organisation responsible for the site) Year (that the site was created or last revised), name and place of the sponsor of the source, viewed Day Month Year,<URL>. e.g. eviQ Cancer Treatments Online 2017, Cancer Institute NSW, viewed 7 March 2017, https://www.eviq.org.au/

To cite a page on the eviQ website:

Title Year, version number (if applicable), description of document (if applicable), name and place of the sponsor of the source, viewed Day Month Year,<URL either full location details or just the main site details> e.g.Clinical resource: Asparaginase 2017 V.2, eviQ Cancer Treatments Online, Cancer Institute NSW, viewed 24th August 2017, eviq.org.au/p/918

Throughout eviQ some chemotherapy drug names have been modified using Tall Man lettering. Medication names that look or sound alike (LASA) have been identified as a common cause of medication errors, some of which caused considerable patient harm. Tall Man lettering uses a combination of lower and upper case letters to highlight the differences between look alike and sound alike drug names e.g. DOXOrubicin and DAUNOrubicin, helping to make them more easily distinguishable. Tall Man lettering aims to reduces the risk of error by warning health care professionals about the possibility of confusing a particular medicine name and by helping health professionals to select the right product in electronic systems or from shelves.

The Australian Commission on Safety and Quality in Health Care (the Commission) supports the use of Tall Man lettering as part of a multi-faceted program to reduce the risks associated with confusable drug names. eviQ aligns with the National Tall Man Lettering List developed by the Australian Commission on Safety and Quality in Health Care.

There is evidence for several mesna doses as well as differing administration timings (e.g. 2, 4, 6, or 8 hours post initiation or completion of the ifosfamide/cyclophosphamide dose) with no clear evidence that one particular regimen is superior over another. The eviQ mesna recommendations may be based upon the individual trial/study or eviQ Reference Committee consensus and provide guidance on one safe way to administer the protocol. Individual institutional policy may vary and should be evidence based.